News


March 23rd, 2017

Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – March 22nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to SSI therapy. […]

READ MORE >
March 21st, 2017

Administrative Assistant

TERMS OF EMPLOYMENT This is a full-time position (1.0 FTE) COMPANY PROFILE Qu Biologics is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse the chronic inflammation underlying many conditions including cancer and inflammatory bowel diseases (IBD). […]

READ MORE >
March 3rd, 2017

Qu Biologics Discovers Correlation Between Patient Genetics and Response to Immunotherapy in Inflammatory Bowel Disease

Vancouver, British Columbia – March 3, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, reports positive genetic analyses of their recently completed Phase 2 clinical studies in Crohn’s Disease (CD) and Ulcerative Colitis (UC). These findings suggest that, for the first […]

READ MORE >
February 17th, 2017

Biotechnology Post-Doctoral Research Fellow

TERMS OF EMPLOYMENT This is a full-time position (1.0 FTE) with the University of British Columbia (UBC) COMPANY PROFILE Qu Biologics is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse the chronic inflammation underlying many conditions […]

READ MORE >
January 30th, 2017

Data Project Manager

TERMS OF EMPLOYMENT This is a full-time position (1.0 FTE) COMPANY PROFILE Qu Biologics is a private, clinical-stage biopharmaceutical company located in Vancouver, BC, that develops Site Specific Immunomodulators (SSIs) which are designed to restore the body’s normal immune function to reverse the chronic inflammation underlying many conditions including cancer and inflammatory bowel diseases (IBD). […]

READ MORE >
October 13th, 2016

Qu Biologics Publishes Promising Paper on Novel Treatment for Allergic Airway Disease

Vancouver, British Columbia – Oct. 13, 2016 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, announces the publication, today, of a paper in Nature Publishing Groups’ Scientific Reports. This peer-reviewed study, in collaboration with Dr. Jeremy Hirota’s laboratory at the University of British […]

READ MORE >
April 12th, 2016

Qu Biologics Closes Private Financing of CDN$4 Million

Vancouver, British Columbia – April 12, 2016 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, announced it has closed a private financing of CDN$4 million bringing the total private equity capital raised to CDN$23 million to date, including more than CDN$7 million […]

READ MORE >
April 6th, 2016

Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis

Vancouver, British Columbia – April 6, 2016 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, announced it has been awarded funding of $240,000 from Genome British Columbia (Genome BC) to support a Phase 2a clinical trial of Qu Biologics’ QBECO SSI for […]

READ MORE >
March 21st, 2016

Qu Biologics Announces Initial Results in Randomized, Placebo-Controlled Crohn’s Disease Clinical Trial

Vancouver, British Columbia – March 21, 2016 – Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced initial results from the QBECO-01 study, a 68-patient randomized, placebo-controlled clinical study for the treatment of moderate-to-severe Crohn’s disease. Based on the Week 8 and preliminary Week 16 results, […]

READ MORE >
December 23rd, 2015

Qu Biologics Closes Oversubscribed Financing; Crohn’s Disease Phase 2 Clinical Trial Results in First Quarter 2016

Vancouver, British Columbia – December 23, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, announced it has closed an oversubscribed private financing of CDN$3.5 million bringing the total private equity capital raised to $19 million to date. Dr. Hal Gunn, CEO […]

READ MORE >

Past events:


Past events: